Context Therapeutics to Present Preclinical Data on CT-202 at AACR 2026
Event summary
- Context Therapeutics will present preclinical data on CT-202, a Nectin-4 x CD3 TCE bispecific antibody, at the AACR Annual Meeting 2026.
- The poster presentation is scheduled for April 21, 2026, during the Clinical Research session.
- CT-202 targets Nectin-4, a cell surface protein overexpressed in bladder, colorectal, lung, and breast cancers.
- Context Therapeutics aims to differentiate CT-202 with pH-dependent activation within the tumor microenvironment.
The big picture
Context Therapeutics is focusing on T cell engaging bispecific antibodies for solid tumors, a competitive space where differentiation through mechanisms like pH-dependent activation could be key. The presentation at AACR 2026 is a critical step in validating CT-202's potential, especially as the company aims to build a portfolio of innovative therapeutics targeting various solid tumor markers.
What we're watching
- Clinical Validation
- How the preclinical data on CT-202 will influence investor confidence and potential partnerships.
- Competitive Positioning
- Whether Context Therapeutics can differentiate CT-202 from existing Nectin-4 targeted therapies like ADCs.
- Regulatory Pathway
- The pace at which Context Therapeutics advances CT-202 towards clinical trials and potential approval.
Related topics